Abstract
Background This study evaluates longitudinal associations between glycaemic control (mean and within-patient variability of glycated haemaglobin (HbA1c) levels) in individuals with type 2 diabetes (T2D) and major depressive disorder (MDD), focusing on the timings of these diagnoses.
Methods In UK Biobank, T2D was defined using self-report and linked health outcome data, then validated using polygenic scores. Repeated HbA1c measurements (mmol/mol) over the 10 years following T2D diagnosis were outcomes in mixed effects models, with T2D disease duration included using restricted cubic splines. Four MDD exposures were considered: MDD diagnosis prior to T2D diagnosis (pre-T2D MDD), time between pre-T2D MDD diagnosis and T2D, new MDD diagnosis during follow-up (post-T2D MDD) and time since post-T2D MDD diagnosis. Models with and without covariate adjustment were considered.
Results T2D diagnostic criteria were robustly associated with T2D polygenic scores. In 11,837 T2D cases (6.9 year median follow-up), pre-T2D MDD was associated with a 0.92 increase in HbA1c (95% CI: [0.00, 1.84]), but earlier pre-T2D MDD diagnosis correlated with lower HbA1c. These pre-T2D MDD effects became non-significant after covariate adjustment. Post-T2D MDD individuals demonstrated increasing HbA1c with years since MDD diagnosis (/3 = 0.51, 95% CI: [0.17, 0.86]). Retrospectively, looking across all follow-up, within-patient variability in HbA1c was 1.16 (95% CI: 1.13-1.19) times higher in post-T2D MDD.
Conclusions The timing of MDD diagnosis is important for understanding glycaemic control in T2D. Poorer control was observed in MDD diagnosed post-T2D, highlighting the importance of depression screening in T2D, and closer monitoring for individuals who develop MDD after T2D.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This paper represents independent research part-funded by the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. The authors acknowledge use of the research computing facility at King's College London, CREATE. This research as supported by the Medical Research Council (MR/S0151132; MR/N015746). JT and FC are supported by an Academy of Medical Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust, GCRF, the Government Department of Business, Energy and Industrial strategy, the British Heart Foundation and Diabetes UK [SBF004\1079]. KGY is supported by Research England's Expanding Excellence in England (E3) fund. HG is funded by an E3 Independent Research Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted by the NHS North West Research Ethics Committee (REC reference 11/NW/0382). Written informed consent was obtained from all participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
‡ joint senior authors
Major revisions. The exposure variables were updated. Previously a 3 level retrospective factor was used as the exposure: 1) no MDD (no MDD diagnosis before T2D diagnosis, or during follow-up), 2) pre-T2D MDD (MDD diagnosis occurring prior to T2D diagnosis) and 3) post-T2D MDD (MDD diagnosis occurring after T2D diagnosis- i.e. during follow up). Exposures were updated to: 1) MDD at baseline (binary variable indicating MDD at baseline- this captures the pre-T2D MDD individuals), 2) time between pre-T2D MDD and T2D diagnosis (semi-continuous variable), 3) time-varying post-T2D MDD binary variable and 4) time since post-T2D MDD (Semi-continuous variable). Note. The retrospective variable was still utilised in one model when looking at impact of MDD on residual variation. Whilst the exposures are now more complex, they offer a more nuanced exploration of the impact of MDD on HbA1c in individuals with T2D. Secondly, issues around not adjusting for potentially impactful confounders were addressed. For example, BMI, SBP and DBP approximately at T2D diagnosis extracted and added into the model as covariates. Thirdly, the imputation model was updated to include more auxiliary covariates. Changes, particularly to the exposures, changed results and therefore the manuscript was re-written. Code is available (GitHub repo- see manuscript for location). Polygenic score work was removed, primarily due to space and simplification of results communication.
Data Availability
Data is available from UK Biobank subject to standard access procedures (www.ukbiobank.ac.uk).
List of abbreviations
- HbA1c
- Glycated haemaglobin
- T2D
- Type 2 diabetes
- MDD
- Major depressive disorder
- UKB
- UK Biobank
- GP
- General practioner
- PGS
- Polygenic score
- BMI
- Body mass index
- SBP
- Systolic blood pressure
- DBP
- Diastolic blood pressure
- MEM
- Mixed effects model
- CAR1
- Continuous-time autoregressive 1
- LRT
- Likelihood ratio test
- MI
- Multiple imputation
- CI
- Confidence interval
- IQR
- Interquartile range
- HES
- Hospital episode statistics
